New drug combo targets Hard-to-Treat lung cancer
NCT ID NCT07549061
First seen Apr 29, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study tests a new drug, vebreltinib, combined with standard chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has a specific marker (MET overexpression) and no other treatable gene changes. The goal is to see if the combination shrinks tumors and controls the disease. About 19 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
241 West Huaihai Road, Xuhui District, Shanghai, 200030, China.
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.